Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; tetraxetan; water for injections - dotagraf is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; tetraxetan; water for injections - dotagraf is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - omalizumab, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 20; histidine; arginine hydrochloride; histidine hydrochloride monohydrate; water for injections - allergic asthma,children 6 to < 12 years of age - in children aged 6 to <12 years, xolair is indicated as add-on therapy to improve asthma control in patients with severe allergic asthma who have documented exacerbations despite daily high dose inhaled corticosteroids, and who have immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,adults and adolescents 12 years of age and above -xolair is indicated for the management of adult and adolescent patients with moderate to severe allergic asthma, who are already being treated with inhaled steroids, and who have serum immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,chronic rhinosinusitis with nasal polyps (crswnp),xolair is indicated as add-on treatment in adult patients (18 years of age and above) for the treatment of severe crswnp with inadequate response to intranasal corticosteroids. recommended dosing is determined by serum immunoglobulin e levels and body weight corresponding to the recommended dose range in the product information (see section 4.2 dose and method of administration).,chronic spontaneous urticaria (csu),xolair is indicated for adults and adolescents (12 years of age and above) with chronic spontaneous urticaria who remain symptomatic despite h1 antihistamine treatment.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - omalizumab, quantity: 75 mg - injection, solution - excipient ingredients: arginine hydrochloride; water for injections; histidine; histidine hydrochloride monohydrate; polysorbate 20 - allergic asthma,children 6 to < 12 years of age - in children aged 6 to <12 years, xolair is indicated as add-on therapy to improve asthma control in patients with severe allergic asthma who have documented exacerbations despite daily high dose inhaled corticosteroids, and who have immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,adults and adolescents 12 years of age and above -xolair is indicated for the management of adult and adolescent patients with moderate to severe allergic asthma, who are already being treated with inhaled steroids, and who have serum immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,chronic rhinosinusitis with nasal polyps (crswnp),xolair is indicated as add-on treatment in adult patients (18 years of age and above) for the treatment of severe crswnp with inadequate response to intranasal corticosteroids. recommended dosing is determined by serum immunoglobulin e levels and body weight corresponding to the recommended dose range in the product information (see section 4.2 dose and method of administration).,chronic spontaneous urticaria (csu),xolair is indicated for adults and adolescents (12 years of age and above) with chronic spontaneous urticaria who remain symptomatic despite h1 antihistamine treatment.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium acetate, quantity: 0.164 g/ml - injection, concentrated - excipient ingredients: water for injections - sodium acetate concentrated injection is indicated for inclusion in total parenteral nutrition (tpn) solutions as an electrolyte source. sodium acetate may also be added to parenteral solution to increase ph. sodium acetate concentrated injection may be used for the treatment of hyponatraemia (sodium depletion) states, in cases where oral sodium therapy is contraindicated or not tolerated.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; water for injections - ondansetron (tablets, syrup, wafers, suppository and injection) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy ondersertron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; water for injections - ondansetron (tablets, syrup, wafers, suppository and injection) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy ondersertron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - hyoscine butylbromide, quantity: 20 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - spasm of the gastrointestinal tract, biliary spasm, renal spasm, diagnostic aid in radiology.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 2.5 mg/ml (equivalent: ondansetron, qty 2 mg/ml) - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; sodium citrate dihydrate; water for injections - ondansetron injection is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 2.5 mg/ml (equivalent: ondansetron, qty 2 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid monohydrate; sodium citrate dihydrate - ondansetron injection is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.